ISONIAZID

Post-LOE

isoniazid

ANDAORALSYRUP
Approved
Nov 1983
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
8

Mechanism of Action

Mechanism of Action Isoniazid inhibits the synthesis of mycoloic acids, an essential component of the bacterial cell wall. At therapeutic levels isoniazid is bactericidal against actively growing intracellular and extracellular Mycobacterium tuberculosis organisms. Resistance Resistance to…

Pharmacologic Class:

Antimycobacterial

Clinical Trials (5)

NCT03886701Phase 1Completed

Doravirine, Rifapentine and Isoniazid Interaction

Started Apr 2019
11 enrolled
Latent TuberculosisHuman Immunodeficiency VirusRifamycins Causing Adverse Effects in Therapeutic Use+1 more
NCT02832778Phase 1Unknown

Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid

Started Nov 2016
35 enrolled
HIV
NCT01936831Phase 2Completed

High-Dose Isoniazid Among Adult Patients With Different Genetic Variants of INH-Resistant Tuberculosis (TB)

Started Aug 2014
NCT01399788Phase 1Completed

A Bioequivalence Study Comparing A Fixed Dose Combination Formulation Of Myrin P Forte That Contains Rifampicin, Isoniazid, Ethambutol And Pyrazinamide Per Tablet To An Equivalent Dose Of Single Drug Reference Preparations Of Similar Combination Following Oral Administration In Healthy Adults

Started Jul 2011
36 enrolled
Healthy Volunteers
NCT01311505Phase 1Completed

Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination (Rifampicin+Isoniazid, Myrin© 2) And The Reference Drug (Rifampicin, Rimactane®)

Started Apr 2011
21 enrolled
Tuberculosis